Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Inclusion Criteria:

• Written informed consent obtained to participate in the study and HIPAAauthorization for release of personal health information.

• Histologically or cytologically confirmed adenocarcinoma of the pancreas with noevidence of distant metastatic disease.

• Subject has no evidence of co-morbidities precluding the potential to undergosurgical resection of PDAC as determined by surgical investigator.

• Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guidedcore biopsy of the pancreatic mass.

• Measurable or non-measurable but evaluable (as determined by Response EvaluationCriteria in Solid Tumors version 1.1 [RECIST 1.1]) resectable, borderline resectableor unresectable locally advanced PDAC.

• Subject has adequate performance status as defined by ECOG performance status 0 or

• Subject has received no prior chemotherapy or chemoradiotherapy for pancreaticcancer. Subjects have not previously received surgery to remove pancreatic cancer.

• Age ≥ 18 years of age.

• Subject has adequate organ function at study entry, as demonstrated by:

• Hemoglobin ≥ 9 g/dL

• ANC ≥ 1.5 × 109/L

• Platelets ≥ 100 × 109/L

• Creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/min (as measuredaccording to Cockcroft-Gault equation)

• Total bilirubin ≤ 1.5 × ULN

• AST/ALT ≤ 3 × ULN

• GGT ≤ 5 × ULN.

• Subject has life expectancy of at least 6 months.

• Female subjects of childbearing potential must have a negative serum or urinepregnancy test performed within 14 days prior to initiation of FOLFIRINOX.

• Female subjects of childbearing potential and male subjects must agree to useadequate contraception prior to study entry, for the duration of studyparticipation, and 8 weeks after the end of treatment.

Exclusion Criteria:

• Subject has any evidence of local recurrence or metastatic pancreatic cancer.

• Other malignancies within the past 5 years except for adequately treated cervical orvulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).

• Subject has hypersensitivity to 5FU, oxaliplatin or other platinum agent, oririnotecan or to their excipients.

• Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.

• Participation in any investigational drug study within 4 weeks preceding the startof study treatment. Subjects are not permitted to participate in anotherinvestigational drug study while being treated on this protocol.

• Subject has current evidence of any condition that makes participating in this studynot in the best interest of the subject, including but not limited to:

• Myocardial infarction within the past 6 months

• New York Heart Association (NYHA) Class III or IV heart disease

• Active infection requiring IV antibiotics

• Subject has a history of or suspected Gilbert's syndrome or known homozygosity forUGT1A1*28 polymorphism (baseline testing not required).

• Subject has sensory peripheral neuropathy grade ≥ 2.

• Major surgery, open biopsy or significant traumatic injury within 4 weeks of firststudy drug.

• Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort.Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin isdiscouraged, but not contraindicated. If subjects require phenytoin, carbamazepineor phenobarbital monitoring of drug levels is suggested during the study.

• Subject is pregnant or lactating.

• Psychological, familial, sociological or geographical condition potentiallyhampering compliance with the study protocol and follow-up schedule; thoseconditions should be discussed with the subject before registration in the trial.